34.236.192.4
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Dry Eye/OSD

FDA accepts investigational new drug application for dry eye drop

Posted on September 29, 2020

The U.S. Food and Drug Administration (FDA) accepted an investigational new drug application for AR-15512 (Aerie Pharmaceuticals, Inc) for dry eye. AR-15512 regulates tear production and blink rate.

“The acceptance of the IND for AR-15512 marks the first clinical-stage dry eye product candidate for Aerie, another important milestone for the company. We expect to commence a Phase 2b clinical study, which will be powered as a Phase 3, later this year, with a topline readout expected in the third quarter of 2021,” said Vicente Anido, Jr., PhD, Chairman and Chief Executive Officer at Aerie, in a press release.

Read the full press release here.

-Advertisement-
Related Articles
Not All DED Patients Have Chronic Symptoms
Aug 02, 2021
Dry Eye Awareness Month: Focus on these 3 Goals
Jul 27, 2021
Systane iLux non-inferior to Lipiflow in change in meibomian gland score
Jul 25, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-